Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach

Current Medical Research and Opinion

Volumn 27, Issue 8, 2011, Pages 1563-1570

  Zeymer, Uwe ^a,b   Jünger, Claus ^a   Zahn, Ralf ^b   Bauer, Timm ^b   Bestehorn, Kurt ^c   Senges, Jochen ^b   Gitt, Anselm ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KLINIKUM LUDWIGSHAFEN   (Germany)

^c MSD   (Germany)

Author keywords

Myocardial infarction; Polypill; Prognosis; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; RAMIPRIL; SIMVASTATIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PROSPECTIVE STUDY; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVOR; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; REGISTRIES; SURVIVAL RATE; TIME FACTORS;

EID: 79960391242     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.590969     Document Type: Article

References (19)

1. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-660.
2. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA guidelines for the patients with unstable angina/non-ST-elevation myocardial infarction. Circulation 2007;116:e148-e304.
3. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 2008;29:2909-45.
4. Kushner F, Hand M, Smith S, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update). J Am Coll Cardiol 2009; 54:2205-41.
5. Rottlaender D, Scherner M, Schneider T, et al. Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany. Dtsch Med Wschr 2007;132:139-44. (Pubitemid 46405884)
6. Bosworth HB. Medication treatment adherence. In: Bosworth, et al. (eds) Patient Treatment Adherence. New York: Routledge 2003;147-90.
7. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419-24.
8. The Indian Polycap Study. Effects of a polypill on risk factors in middle-aged individuals without cardiovascular disease: a phase II, double-blind randomized trial. Lancet 2009;373:1341-51.
9. Antithrombotic trialists' collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002;324:71-86.
10. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Circulation 1998;97:2202-12.
11. Cholesterol treatment trialists' collaborators. Efficacy and safety of cholesterol-lowering treatment: a prospective meta-analysis of data from 90,056 patients in 14 randomised trials with statins. Lancet 2005;366:1267-78.
12. Zeymer U, Gitt AK, Jü nger C, et al. Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice. Eur Heart J 2006;27:2661-6. (Pubitemid 44729865)
13. Montalescot G, Dallongeville J, van Belle E, et al. STEMI and NSTEMI: are they so different: 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition. Eur Heart J 2007;28:1409-17. (Pubitemid 47343817)
14. Fonarow C, French WJ, Frederick PD. Trends in the use of lipid-lowering medications at discharge in patients with acute myocardial infarction: 1998 to. 2006. Am Heart J 2009;157:185-94.
15. Rosengren A, Wallentin L, Simoons M, et al. Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey. Eur Heart J 2006;27:789-95.
16. Sanz G, Fuster V. Fixed dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nature Clin Pract Cardiovasc Med 2009;6:101-10.
17. Fuster V. Prime time for a polypill after myocardial infarction. Nature Clin Pract Cardiovasc Med 2009;6:83.
18. Danchin N, Cambou J, Hanania G, et al. Impact of combined secondary prevention after myocardial infarction. Data from a nationwide French registry. Am Heart J 2005;150:1147-53. (Pubitemid 41773515)
19. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Effects of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004; 18:781-8 (Pubitemid 39530090)